Chronic inflammation of tuberculosis

Anas Khalil, Kuan Jen Bai, Shawn Hsiang Yin Chen

研究成果: 書貢獻/報告類型章節

摘要

Managing Tuberculosis (TB) infection remains a challenge and there is a need for modern science to infuse new principles. Better use of existing medications, at the stage without effective vaccines and newly developed medications, is a field in urgent need of research effort. This classical infectious disease, in year 2011 alone, actively infected 8.7 million people and 1.4 million people died. TB and human immunodeficiency virus (HIV) HIV co-infection, multidrug-resistant (MDR) as well as extensively drug-resistant (XDR) TB, and clinically significant adverse drug reactions resulting from long-term medication treatment, altogether contributes to complex treatment problems and TB control challenges worldwide. Pharmacogenetics, together with pharmacoepidemiology studies, would help establish better clinical strategies for evaluating, treating, and monitoring tuberculosis patients. Factors affecting the treatment outcome of TB would be an important domain for clinical research. These include reducing patient default from anti-TB treatment, enhancing the adherence of medication administration, improving the cure rate, avoiding TB relapse, and preventing activation of TB infection. Research efforts thus are warranted to investigate the potential risk factors for TB infection from many aspects: comorbidities, social-economic status, health-related behaviors, occupations, use of certain immunosuppressing medications and genetic involvement. For example, monitoring some genetic variations at some loci of the essential liver enzymes, for instance: monitoring the N-acetlytransferase 2 (NAT2), Cytochrome P450 oxidase (CYP2E1), glutathione S-transferases family (GSTs) that metabolizes and detoxifies anti- TB drugs would give good information about these drug responses and their toxicity. Further, this would help to design personalized medicine for TB in the future.
原文英語
主出版物標題Chronic Inflammation: Causes, Treatment Options and Role in Disease
發行者Nova Science Publishers, Inc.
頁面171-194
頁數24
ISBN(列印)9781628080940
出版狀態已發佈 - 2013

指紋

Tuberculosis
Inflammation
Infection
Extensively Drug-Resistant Tuberculosis
Pharmacoepidemiology
Research
HIV
Cytochrome P-450 CYP2E1
Precision Medicine
Medication Adherence
Pharmacogenetics
Physiologic Monitoring
Electron Transport Complex IV
Virus Diseases
Glutathione Transferase
Drug-Related Side Effects and Adverse Reactions
Coinfection
Occupations
Pharmaceutical Preparations
Cytochrome P-450 Enzyme System

ASJC Scopus subject areas

  • Medicine(all)

引用此文

Khalil, A., Bai, K. J., & Chen, S. H. Y. (2013). Chronic inflammation of tuberculosis. 於 Chronic Inflammation: Causes, Treatment Options and Role in Disease (頁 171-194). Nova Science Publishers, Inc..

Chronic inflammation of tuberculosis. / Khalil, Anas; Bai, Kuan Jen; Chen, Shawn Hsiang Yin.

Chronic Inflammation: Causes, Treatment Options and Role in Disease. Nova Science Publishers, Inc., 2013. p. 171-194.

研究成果: 書貢獻/報告類型章節

Khalil, A, Bai, KJ & Chen, SHY 2013, Chronic inflammation of tuberculosis. 於 Chronic Inflammation: Causes, Treatment Options and Role in Disease. Nova Science Publishers, Inc., 頁 171-194.
Khalil A, Bai KJ, Chen SHY. Chronic inflammation of tuberculosis. 於 Chronic Inflammation: Causes, Treatment Options and Role in Disease. Nova Science Publishers, Inc. 2013. p. 171-194
Khalil, Anas ; Bai, Kuan Jen ; Chen, Shawn Hsiang Yin. / Chronic inflammation of tuberculosis. Chronic Inflammation: Causes, Treatment Options and Role in Disease. Nova Science Publishers, Inc., 2013. 頁 171-194
@inbook{83d2fb0370ca46e0ab9d7b6f7c02deeb,
title = "Chronic inflammation of tuberculosis",
abstract = "Managing Tuberculosis (TB) infection remains a challenge and there is a need for modern science to infuse new principles. Better use of existing medications, at the stage without effective vaccines and newly developed medications, is a field in urgent need of research effort. This classical infectious disease, in year 2011 alone, actively infected 8.7 million people and 1.4 million people died. TB and human immunodeficiency virus (HIV) HIV co-infection, multidrug-resistant (MDR) as well as extensively drug-resistant (XDR) TB, and clinically significant adverse drug reactions resulting from long-term medication treatment, altogether contributes to complex treatment problems and TB control challenges worldwide. Pharmacogenetics, together with pharmacoepidemiology studies, would help establish better clinical strategies for evaluating, treating, and monitoring tuberculosis patients. Factors affecting the treatment outcome of TB would be an important domain for clinical research. These include reducing patient default from anti-TB treatment, enhancing the adherence of medication administration, improving the cure rate, avoiding TB relapse, and preventing activation of TB infection. Research efforts thus are warranted to investigate the potential risk factors for TB infection from many aspects: comorbidities, social-economic status, health-related behaviors, occupations, use of certain immunosuppressing medications and genetic involvement. For example, monitoring some genetic variations at some loci of the essential liver enzymes, for instance: monitoring the N-acetlytransferase 2 (NAT2), Cytochrome P450 oxidase (CYP2E1), glutathione S-transferases family (GSTs) that metabolizes and detoxifies anti- TB drugs would give good information about these drug responses and their toxicity. Further, this would help to design personalized medicine for TB in the future.",
author = "Anas Khalil and Bai, {Kuan Jen} and Chen, {Shawn Hsiang Yin}",
year = "2013",
language = "English",
isbn = "9781628080940",
pages = "171--194",
booktitle = "Chronic Inflammation: Causes, Treatment Options and Role in Disease",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Chronic inflammation of tuberculosis

AU - Khalil, Anas

AU - Bai, Kuan Jen

AU - Chen, Shawn Hsiang Yin

PY - 2013

Y1 - 2013

N2 - Managing Tuberculosis (TB) infection remains a challenge and there is a need for modern science to infuse new principles. Better use of existing medications, at the stage without effective vaccines and newly developed medications, is a field in urgent need of research effort. This classical infectious disease, in year 2011 alone, actively infected 8.7 million people and 1.4 million people died. TB and human immunodeficiency virus (HIV) HIV co-infection, multidrug-resistant (MDR) as well as extensively drug-resistant (XDR) TB, and clinically significant adverse drug reactions resulting from long-term medication treatment, altogether contributes to complex treatment problems and TB control challenges worldwide. Pharmacogenetics, together with pharmacoepidemiology studies, would help establish better clinical strategies for evaluating, treating, and monitoring tuberculosis patients. Factors affecting the treatment outcome of TB would be an important domain for clinical research. These include reducing patient default from anti-TB treatment, enhancing the adherence of medication administration, improving the cure rate, avoiding TB relapse, and preventing activation of TB infection. Research efforts thus are warranted to investigate the potential risk factors for TB infection from many aspects: comorbidities, social-economic status, health-related behaviors, occupations, use of certain immunosuppressing medications and genetic involvement. For example, monitoring some genetic variations at some loci of the essential liver enzymes, for instance: monitoring the N-acetlytransferase 2 (NAT2), Cytochrome P450 oxidase (CYP2E1), glutathione S-transferases family (GSTs) that metabolizes and detoxifies anti- TB drugs would give good information about these drug responses and their toxicity. Further, this would help to design personalized medicine for TB in the future.

AB - Managing Tuberculosis (TB) infection remains a challenge and there is a need for modern science to infuse new principles. Better use of existing medications, at the stage without effective vaccines and newly developed medications, is a field in urgent need of research effort. This classical infectious disease, in year 2011 alone, actively infected 8.7 million people and 1.4 million people died. TB and human immunodeficiency virus (HIV) HIV co-infection, multidrug-resistant (MDR) as well as extensively drug-resistant (XDR) TB, and clinically significant adverse drug reactions resulting from long-term medication treatment, altogether contributes to complex treatment problems and TB control challenges worldwide. Pharmacogenetics, together with pharmacoepidemiology studies, would help establish better clinical strategies for evaluating, treating, and monitoring tuberculosis patients. Factors affecting the treatment outcome of TB would be an important domain for clinical research. These include reducing patient default from anti-TB treatment, enhancing the adherence of medication administration, improving the cure rate, avoiding TB relapse, and preventing activation of TB infection. Research efforts thus are warranted to investigate the potential risk factors for TB infection from many aspects: comorbidities, social-economic status, health-related behaviors, occupations, use of certain immunosuppressing medications and genetic involvement. For example, monitoring some genetic variations at some loci of the essential liver enzymes, for instance: monitoring the N-acetlytransferase 2 (NAT2), Cytochrome P450 oxidase (CYP2E1), glutathione S-transferases family (GSTs) that metabolizes and detoxifies anti- TB drugs would give good information about these drug responses and their toxicity. Further, this would help to design personalized medicine for TB in the future.

UR - http://www.scopus.com/inward/record.url?scp=84892077795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892077795&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84892077795

SN - 9781628080940

SP - 171

EP - 194

BT - Chronic Inflammation: Causes, Treatment Options and Role in Disease

PB - Nova Science Publishers, Inc.

ER -